[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336392-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-336392-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","claudin-18-status-and-its-correlation-with-her2-and-pd-l1-expression-in-gastric-cancer-with-peritoneal-dissemination","Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination","","Gastric cancer with peritoneal dissemination has a poor prognosis and limited treatment efficacy. This study evaluates CLDN18.2 status in peritoneal dissemination (PD)-positive gastric cancers and examines how CLDN18 expression relates to HER2 and PD-L1 combined positive score (CPS). Immunohistochemistry was performed on paired primary and PD tissues from 84 cases. CLDN18 positivity showed substantial primary–PD concordance and remained relatively high even in HER2-negative and double-negative subgroups.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/claudin-18-status-and-its-correlation-with-her2-and-pd-l1-expression-in-gastric-cancer-with-peritoneal-dissemination/336392/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/claudin-18-status-and-its-correlation-with-her2-and-pd-l1-expression-in-gastric-cancer-with-peritoneal-dissemination/336392.png","ImageObject",300,407,{"name":42,"@type":43},"Violet","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study aim regarding CLDN18 in PD-positive gastric cancer?","Question",{"text":63,"@type":64},"To analyze CLDN18 status in both primary and PD tissues and assess its correlation with HER2 and PD-L1 CPS to evaluate potential applicability of CLDN18.2-targeted therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was CLDN18 status assessed in this research?",{"text":68,"@type":64},"Immunohistochemical analysis was performed on 84 gastric cancer cases using paired primary and PD tissue samples, applying cut-off levels of 40% and 75%.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key concordance findings between primary tumors and PD lesions?",{"text":72,"@type":64},"Concordance was 79.8% at the 40% cut-off and 75% at the 75% cut-off, indicating generally maintained CLDN18 expression in PD.",{"name":74,"@type":61,"acceptedAnswer":75},"Why is CLDN18 considered promising even in double-negative tumors?",{"text":76,"@type":64},"The study found relatively high CLDN18 positivity rates among HER2-negative and double-negative (HER2− and PD-L1 CPS \u003C 1) tumors, supporting CLDN18 as a potential therapeutic target.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},336392,1790167718,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":119,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},4398048950312,"https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","Gastric Cancer (2024) 27:802–810  \n[https://doi.org/10.1007/s10120-024-01505-6](https://doi.org/10.1007/s10120-024-01505-6)  \nClaudin‑18 status and its correlation with HER2 and PD‑L1 expression in gastric cancer with peritoneal dissemination  \nHaruki Ogawa1,2 · Hiroyuki Abe1 · Koichi Yagi2 · Yasuyuki Seto2 · Tetsuo Ushiku1  \nReceived: 6 October 2023 / Accepted: 27 April 2024 / Published online: 9 May 2024 © The Author(s) 2024  \nAbstract  \nBackground Gastric cancer with peritoneal dissemination (PD) has a dismal prognosis, and current treatments have shown little efficacy. CLDN18.2-targeted therapies have shown promising efficacy against gastric cancers that express high levels of CLDN18. Because of the limited information regarding CLDN18.2 status in PD, we analyzed PD-positive gastric cancers for CLDN18 status in both primary and PD, along with HER2 and PD-L1 combined positive score (CPS) .  \nMethods Immunohistochemical analyses were performed on 84 gastric cancer cases using paired primary and PD tissue samples.  \nResults At 40% cut-off, CLDN18 was positive in 57%(48/84) primary tumors and in 44%(37/84) PDs. At 75% cut-off, 28.6%(24/84) primary tumors and 20.2%(17/84) PDs were CLDN18-positive. The concordance rate between primary tumors and PD was 79.8% at 40% cut-off and 75% at 75% cut-off. When comparing biopsy and surgical specimens, the concordance rates were 87.5% at 40% cut-off and 81.3% at 75% cut-off. Within a tumor, the superficial area tended to have a higher CLDN18-positive rate than the invasive front (P = 0.001) . Although HER2-positivity was only 11.9% in this cohort, CLDN18 positivity in HER2-negative tumors (n = 74) was relatively high: 60.8% at 40% cut-off and 28.4% at 75% cut-off. Among double-negative (HER2 − and PD-L1 CPS \u003C 1) tumors, CLDN18 positivity was 67.6% at 40% cut-off and 26.5% at 75% cut-off.  \nConclusions CLDN18 expression is generally maintained in PD and is relatively high even in double-negative tumors, making it a promising therapeutic target for PD-positive gastric cancer.  \nKeywords Gastric cancer · Claudin-18 · Peritoneal dissemination · Molecular targeted therapy · Immunohistochemistry  \nIntroduction  \nGastric cancer is the fourth leading cause of cancer-related deaths worldwide [1] . The morbidity and mortality rates are declining because of the decreasing prevalence of Helicobacter pylori infection, widespread H.pylori eradication therapy, and early detection through endoscopy. However,  \nHaruki Ogawa and Hiroyuki Abe equally contributed to this work.  \n* Tetsuo Ushiku[usikut@g.ecc.u-tokyo.ac.jp](usikut@g.ecc.u-tokyo.ac.jp)  \n1 Department of Pathology, Graduate School of Medicine, the University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo 113-0033, Japan  \n2 Department of Gastrointestinal Surgery, Graduate School of Medicine, the University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo 113-0033, Japan  \nthe prognosis of patients with advanced gastric cancer, especially those with peritoneal dissemination (PD), is still poor [2] . Chemotherapy, anti-human epidermal growth factor receptor 2 (HER2) antibodies (such as trastuzumab), antiVEGFR2 antibodies (such as ramucirumab), and immune checkpoint inhibitors are standard therapies for unresectable or recurrent gastric cancer. PD-positive gastric cancers typically exhibit a diffuse-type histology and this subtype is HER2-negative in most cases. PD-L1expression is also relatively low in the diffuse-type subtype when compared to the microsatellite instability and Epstein-Barr virus-positive subtypes. Therefore, new treatment strategies for PD-positive gastric cancers are urgently required.  \nRecently, zolbetuximab, which targets the tight junction molecule claudin-18 isoform 2 (CLDN18.2), was developed. Zolbetuximab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds CLDN18.2 and induces antibody-and complement-dependent cellular cytotoxicity. Randomized  \nphase 2 (FAST, NCT01630083) and phase 3 trials (SPOTLIGHT, NCT03504397, and GLOW, NCT","cbCaitcNeEMFX9pQ","https://ap.wps.com/l/cbCaitcNeEMFX9pQ","pdf",2264009,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusions\n# Keywords\n# Introduction","[{\"question\":\"What was the study aim regarding CLDN18 in PD-positive gastric cancer?\",\"answer\":\"To analyze CLDN18 status in both primary and PD tissues and assess its correlation with HER2 and PD-L1 CPS to evaluate potential applicability of CLDN18.2-targeted therapy.\"},{\"question\":\"How was CLDN18 status assessed in this research?\",\"answer\":\"Immunohistochemical analysis was performed on 84 gastric cancer cases using paired primary and PD tissue samples, applying cut-off levels of 40% and 75%.\"},{\"question\":\"What were the key concordance findings between primary tumors and PD lesions?\",\"answer\":\"Concordance was 79.8% at the 40% cut-off and 75% at the 75% cut-off, indicating generally maintained CLDN18 expression in PD.\"},{\"question\":\"Why is CLDN18 considered promising even in double-negative tumors?\",\"answer\":\"The study found relatively high CLDN18 positivity rates among HER2-negative and double-negative (HER2− and PD-L1 CPS \\u003c 1) tumors, supporting CLDN18 as a potential therapeutic target.\"}]","Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination | PDF",1790014833,23,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c592f678000abe281054b3edd72b828e.webp",983,1305,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8702850bd3e0dfd8b6d5b590713fb833.webp",982,1304,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a148358ce92898325df6ab5232c66b25.webp",981,1303,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad38f5b75c0b1812587a62cb3d697dd8.webp",980,1301]